Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 10, 2012, Pages 1471-1478

  Pasquini, Marcelo C ^a   Voltarelli, Julio ^b   Atkins, Harold L ^c   Hamerschlak, Nelson ^d   Zhong, Xiaobo ^a   Ahn, Kwang Woo ^a   Sullivan, Keith M ^e   Carrum, George ^f   Andrey, Jeffrey ^g   Bredeson, Christopher N ^c   Cairo, Mitchell ^h   Gale, Robert Peter ⁱ   Hahn, Theresa ^j   Storek, Jan ^k   Horowitz, Mary M ^a   McSweeney, Peter A ^l   Griffith, Linda M ^m   Muraro, Paolo A ⁱ   Pavletic, Steven Z ⁿ   Nash, Richard A ^o  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF OTTAWA   (Canada)

^d HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g SCRIPPS HEALTH   (United States)

^h NewYork Presbyterian Hospital   (United States)

ⁱ Science and Technology   (United Kingdom)

^j ROSWELL PARK CANCER INSTITUTE   (United States)

^k UNIVERSITY OF CALGARY   (Canada)

^l PRESBYTERIAN ST LUKE S MEDICAL CENTER   (United States)

^m NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁿ NATIONAL CANCER INSTITUTE   (United States)

^o Fred Hutchinson Cancer Research Center   (United States)

more..

Author keywords

Autoimmunity; Autologous transplants; Multiple sclerosis

Indexed keywords

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER SURVIVOR; CAUSE OF DEATH; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; MYASTHENIA GRAVIS; MYELODYSPLASTIC SYNDROME; NORTH AMERICA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRESCHOOL CHILD; RHEUMATOID ARTHRITIS; RISK FACTOR; SCHOOL CHILD; SJOEGREN SYNDROME; SOUTH AMERICA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NORTH AMERICA; PROGNOSIS; SOUTH AMERICA; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84866174558     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.06.003     Document Type: Article

References (47)

1. Muraro P.A., Abrahamsson S.V. Resetting autoimmunity in the nervous system: the role of hematopoietic stem cell transplantation. Curr Opin Investig Drugs 2010, 11:1265-1275.
2. Muraro P.A., Douek D.C., Packer A., et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005, 201:805-816.
3. Cooley H.M., Snowden J.A., Grigg A.P., et al. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy. Arthritis Rheum 1997, 40:1712-1715.
4. Fassas A., Anagnostopoulos A., Kazis A., et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997, 20:631-638.
5. Marmont A.M., van Lint M.T., Gualandi F., et al. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 1997, 6:545-548.
6. Burt R.K., Traynor A.E., Cohen B., et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 1998, 21:537-541.
7. Binks M., Passweg J.R., Furst D., et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure-related mortality and impact on skin disease. Ann Rheum Dis 2001, 60:577-584.
8. McSweeney P.A., Nash R.A., Sullivan K.M., et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002, 100:1602-1610.
9. Tyndall A., Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997, 19:643-645.
10. Farge D., Labopin M., Tyndall A., et al. Autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases: an observational study on 12 years of experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases. Haematologica 2009, 95:284-292.
11. Mancardi G., Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008, 7:626-636.
12. Euler H.H., Marmont A.M., Bacigalupo A., et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996, 88:3621-3625.
13. Snowden J.A., Passweg J., Moore J.J., et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004, 31:482-488.
14. Burt R.K., Oyama Y., Verda L., et al. Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Arthritis Rheum 2004, 50:2466-2470.
15. Daikeler T., Hugle T., Farge D., et al. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant 2009, 44:27-33.
16. De Stefano P., Zecca M., Giorgiani G., et al. Resolution of immune haemolytic anaemia with allogeneic bone marrow transplantation after an unsuccessful autograft. Br J Haematol 1999, 106:1063-1064.
17. Nash R.A., McSweeney P.A., Nelson J.L., et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum 2006, 54:1982-1986.
18. Oyama Y., Papadopoulos E.B., Miranda M., et al. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant 2001, 28:903-905.
19. Strober J., Cowan M.J., Horn B.N. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol 2009, 66:659-661.
20. Lu J.-Q., Storek J., Metz L., et al. Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol 2009, 66:116-120.
21. Slavin S., Nagler A., Varadi G., et al. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 2000, 28:853-857.
22. Griffith L.M., Pavletic S.Z., Tyndall A., et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant 2005, 11:862-870.
23. Atkins H.L., Muraro P.A., van Laar J.M., et al. Autologous hematopoietic stem cell transplantation for autoimmune disease: is it now ready for prime time?. Biol Blood Marrow Transplant 2012, 18:S177-S183.
24. Hamerschlak N., Rodrigues M., Moraes D.A., et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant 2010, 45:239-248.
25. Nash R.A., Bowen J.D., McSweeney P.A., et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003, 102:2364-2372.
26. McGuire T.R., Gwilt P., Manouvilov K., et al. High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation. Int Immunopharmacol 2003, 3:279-283.
27. Nash R.A. Allogeneic HSCT for autoimmune diseases: conventional conditioning regimens. Bone Marrow Transplant 2003, 32(Suppl 1):S77-S80.
28. Nash R.A., McSweeney P.A., Crofford L.J., et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007, 110:1388-1396.
29. Kaplan E. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
30. Burt R.K., Loh Y., Pearce W., et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008, 299:925-936.
31. Burt R.K., Loh Y., Cohen B., et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009, 8:244-253.
32. Burt R.K., Traynor A., Oyama Y., et al. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood 2003, 101:2064-2066.
33. Burt R.K., Traynor A., Statkute L., et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006, 295:527-535.
34. Openshaw H., Lund B.T., Kashyap A., et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000, 6:563-575.
35. Oyama Y., Barr W.G., Statkute L., et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 2007, 40:549-555.
36. Oyama Y., Craig R.M., Traynor A.E., et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005, 128:552-563.
37. Voltarelli J.C., Couri C.E., Stracieri A.B., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007, 297:1568-1576.
38. Snowden J.A., Saccardi R., Allez M., et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012, 47:770-790.
39. Gratwohl A., Passweg J., Bocelli-Tyndall C., et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005, 35:869-879.
40. Mancardi G., Sormani M., Di Gioia M., et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 2012, 18:835-842.
41. Sullivan K.M., Muraro P., Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant 2010, 16:S48-S56.
42. Chen Y., Bord E., Tompkins T., et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009, 361:1067-1074.
43. Lindå H., von Heijne A., Major E.O., et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009, 361:1081-1087.
44. Singh J.A., Wells G.A., Christensen R., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, (2). CD008794.
45. Tappenden P., Saccardi R., Confavreux C., et al. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant 2010, 45:1014-1021.
46. Pavletic S.Z. HSCT for AID: entering prime time?. Blood 2011, 118:1438-1439.
47. Pasquini M.C., Griffith L.M., Arnold D.L., et al. Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant 2010, 16:1076-1083.